Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could special contact lenses slow worsening eyesight in young adults?

NCT ID NCT05955638

Disease control Sponsor: University of Bradford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dual focus contact lenses (MiSight) can slow the progression of nearsightedness (myopia) in university students aged 18 to 21. Participants wear either the test lenses or standard single vision lenses for at least 10 hours a day. Researchers measure changes in eye length and prescription over time to see if the lenses reduce worsening eyesight.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MiSight dual focus soft contact lenses
What this could lead to
If effective, these lenses could offer a way to slow worsening nearsightedness in young adults, reducing the need for stronger prescriptions.
What could go wrong
This is a small, early-stage study in a specific age group. Results may not apply to all myopes, and the lenses may not slow progression for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 21 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be a myopic students studying at university * Be aged 18-21 years at the start of the study * Show evidence of recent myopia progression prior to commencement of Stage 2 of the study. * Have read the patient information sheet and be happy to sign the consent forms * Be willing to adhere to the visit schedule and wearing times described in this protocol * Agree to lens wearing times of at least 10 hours per day, 6 days per week * Agree to accept either the control or test lens as assigned by the randomisation * Have BCVA of +0.10 logMAR or better in each eye Exclusion Criteria: * Previous myopia control use (optical or pharmacological) * Amblyopia * Ocular pathology such as keratoconus or recurrent corneal infections * Myopic Rx \> 10D * Astigmatism \>1D * Anisometropia \>1.75D * Binocular Vision anomalies (such as Tropia) * Medications that affect pupil size or accommodation * A known allergy to fluorescein or tropicamide * Biomicroscopic findings that would contraindicate contact lens wear * The investigator considers that it is not in the best interest of the subject to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

degenerative myopia myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia, progressive

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Bradford

    Bradford, West Yorkshire, BD7, United Kingdom

  • University of Huddersfield

    Huddersfield, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.